Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies

被引：0
|
作者：
Laiyi Chua
Stuart Friedrich
Xin Cindy Zhang
机构：
[1] Eli Lilly and Company,Global PK/PD and Pharmacometrics
来源：
Clinical Pharmacokinetics | 2023年 / 62卷 / 10期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1479 / 1491
页数：12
相关论文
共 50 条
  • [41] Pharmacokinetics and Exposure-Response Relationship of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase2/3 Induction and Maintenance Studies
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Marano, Colleen W.
    Strauss, Richard
    Zhang, Hongyan
    Johanns, Jewel
    Ford, Joyce A.
    Zhou, Honghui
    Davis, Hugh M.
    Colombel, Jean-Frederic
    Reinisch, Walter
    Feagan, Brian G.
    Rutgeerts, Paul J.
    Sandborn, William
    GASTROENTEROLOGY, 2013, 144 (05) : S228 - S229
  • [42] Corticosteroid-Sparing Effect in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab Maintenance Therapy
    Laharie, David
    Siegel, Corey A.
    Samaan, Karen
    Fischer, Deborah
    Morris, Nathan
    Redondo, Isabel
    Dulai, Parambir S.
    Jairath, Vipul
    Gisbert, Javier P.
    Matsuoka, Katsuyoshi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S635 - S635
  • [43] The Impact of Mirikizumab Induction, Maintenance, and Long-Term Treatment on Disease Clearance in Patients With Moderately to Severely Active Ulcerative Colitis: Post-Hoc Analysis of LUCENT Trials
    Colombel, Jean-Frederic
    Kobayashi, Taku
    Wu, Jianmin
    Zhu, Baojin
    Jairath, Vipul
    Redondo, Isabel
    Moses, Richard
    Siegel, Corey A.
    Siegmund, Britta
    Magro, Fernando
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1079 - S1080
  • [44] Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Marano, Colleen W.
    Strauss, Richard
    Zhang, Hongyan
    Johanns, Jewel
    Zhou, Honghui
    Davis, Hugh M.
    Reinisch, Walter
    Feagan, Brian G.
    Rutgeerts, Paul
    Sandbom, William J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (01): : 35 - 46
  • [45] Effects of Immunomodulators on the Pharmacokinetics and Efficacy of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT-SC Induction and Maintenance Studies
    Adedokun, Omoniyi
    Xu, Zhenhua
    Marano, Colleen
    Strauss, Richard
    Zhang, Hongyan
    Johanns, Jewel
    Ford, Joyce
    Zhou, Honghui
    Davis, Hugh
    Colombel, Jean-Frederic
    Reinisch, Walter
    Feagan, Brian
    Rutgeerts, Paul
    Sandborn, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S517 - S517
  • [46] Endoscopic and Histologic Remission After 2 Years Treatment With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis
    Margo, Fernando
    Peyrin-Biroulet, Laurent
    Kobayashi, Taku
    Jairath, Vipul
    Walsh, Alissa
    Christensen, Britt
    Wu, Jianmin
    Park, Gina
    Redondo, Isabel
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S812 - S812
  • [47] Association of Faecal Calprotectin With Symptomatic, Endoscopic, and Clinical Remission in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
    Vermeire, Severine
    Long, Millie D.
    Dulai, Parambir S.
    Ma, Christopher
    Chan-diehl, Faye
    Moses, Richard
    Zhu, Baojin
    Paulissen, Jerome
    Travis, Simon
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S958 - S958
  • [48] Golimumab for moderately to severely active ulcerative colitis
    Kedia, Saurabh
    Ahuja, Vineet
    Makharia, Govind K.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1273 - 1282
  • [49] Guselkumab for moderately to severely active ulcerative colitis
    不详
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 112 - 112
  • [50] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
12345